Foghorn Therapeutics Inc (NASDAQ: FHTX) — Perfil da empresa, notícias e dados financeiros
Foghorn Therapeutics is a biopharmaceutical company leveraging Gene Traffic Control™ to develop cancer therapies.
Foghorn Therapeutics Inc
Foghorn Therapeutics (NASDAQ:FHTX) harnesses its pioneering Gene Traffic Control™ platform to discover and develop innovative therapies targeting diseases with a genetic basis, particularly cancer. The company's mission is centered around unlocking the vast potential of the human genome to revolutionize treatment options for patients battling these serious conditions. Through a deep understanding of chromatin biology, Foghorn Therapeutics strives to lead the way in creating a new wave of precision medicine. Their projects range from early discovery to clinical development, emphasizing a commitment to bringing groundbreaking treatments from the lab bench to bedside.
Resumo
Operações
Produtos e/ou serviços de Foghorn Therapeutics Inc
- FHD-286 for treatment of myeloid leukemia and solid tumors, aiming at enzymatic activity modulation of BRG1 and BRM, part of the chromatin remodeling complex.
- FHD-609, a targeted protein degradation approach focused on inhibiting BRD9, a component of the non-canonical BAF (ncBAF) complex, for treating synovial sarcoma and SMARCB1-null tumors.
- Gene Traffic Control platform, leveraging proprietary insights into the Chromatin Regulatory System to identify novel drug targets and understand disease mechanisms.
- Collaboration with multiple biopharmaceutical companies to use the Gene Traffic Control platform for discovering novel therapeutic targets in various diseases.
- Development of small molecule inhibitors targeting the chromatin remodeling complexes to treat cancers with specific genetic alterations.
- Investigation into the role of chromatin dysregulation in cancer to identify potential therapeutic targets and biomarkers for novel treatments.
equipe executiva do Foghorn Therapeutics Inc
- Douglas G. ColeFounder & Independent Chairman of the Board
- Adrian H. B. GottschalkPresident, CEO & Director
- Steven F. BellonChief Scientific Officer
- Alfonso Quintas CardamaChief Medical Officer
- Gerald R. CrabtreeFounder & Member of Scientific Advisory Board
- Ryan D. MaynardChief Financial Officer
- Karin HellsvikChief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations
- Michael J. LaCasciaChief Legal Officer
- Saurabh SewakVice President of Corporate Development
- Carlos CostaChief People Officer
Principais indicadores financeiros
Resultados divulgados pela Foghorn Therapeutics Inc, em USD.
- Cap. de mercado
- 126,5 mi
- Receita (TTM)
- 36,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.0
- Dividend yield
- —
- Margem de lucro
- -175.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 30,9 mi | -82,1 mi | -74,3 mi | |
| 22,6 mi | -102,7 mi | -86,6 mi | |
| 34,2 mi | -107,9 mi | -98,4 mi | |
| 19,2 mi | -117,1 mi | -108,9 mi |